Zacks Investment Research Upgrades Axsome Therapeutics (NASDAQ:AXSM) to Hold
According to Zacks, “Axsome Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing novel therapies for the management of pain and other central nervous system disorders. Its product candidate portfolio consists of AXS-02 and AXS-05 which are in clinical trial stage. Axsome Therapeutics, Inc. is based in New York. “
A number of other equities analysts have also recently commented on the company. ValuEngine raised Axsome Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, November 1st. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Axsome Therapeutics in a report on Thursday, October 17th. BidaskClub raised Axsome Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, October 26th. Guggenheim initiated coverage on Axsome Therapeutics in a report on Wednesday, October 16th. They issued a “buy” rating and a $48.00 target price on the stock. Finally, William Blair initiated coverage on Axsome Therapeutics in a report on Wednesday, September 18th. They issued an “outperform” rating and a $48.00 target price on the stock. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $35.13.
Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Thursday, November 7th. The company reported ($0.56) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.15). On average, analysts predict that Axsome Therapeutics will post -1.7 earnings per share for the current year.
In other Axsome Therapeutics news, CFO Nick Pizzie purchased 2,180 shares of the business’s stock in a transaction on Thursday, September 26th. The stock was acquired at an average price of $24.80 per share, for a total transaction of $54,064.00. Following the purchase, the chief financial officer now owns 40,440 shares of the company’s stock, valued at approximately $1,002,912. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 27.50% of the company’s stock.
A number of hedge funds have recently modified their holdings of AXSM. Biegel & Waller LLC purchased a new stake in Axsome Therapeutics in the 2nd quarter worth $226,000. Quantitative Systematic Strategies LLC purchased a new stake in Axsome Therapeutics in the 2nd quarter worth $257,000. Virginia Retirement Systems ET AL purchased a new stake in Axsome Therapeutics in the 2nd quarter worth $379,000. Moody Aldrich Partners LLC purchased a new stake in Axsome Therapeutics in the 2nd quarter worth $1,843,000. Finally, SG Americas Securities LLC purchased a new stake in Axsome Therapeutics in the 2nd quarter worth $167,000. Institutional investors and hedge funds own 54.02% of the company’s stock.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.
Read More: Terms to Better Understand Call Options
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.